Establishment of a prediction model of lymph node metastasis in patients with non-small cell lung cancer at high altitude areas based on energy spectrum CT parameters and clinicopathological factors
-
摘要:目的
探讨高海拔地区非小细胞肺癌(NSCLC)患者的淋巴结转移的能谱CT参数、临床病理因素、影响因素及其预测模型的应用效能。
方法选取青海省人民医院2020年1月—2021年7月收治的84例NSCLC患者作为研究对象,其中50例患者进行能谱CT检测并收集临床资料。依据淋巴结转移病理检查结果将50例患者分为转移组、未转移组,采用单因素分析2组患者的临床病理因素、能谱CT参数差异,采用多因素回归分析NSCLC患者发生淋巴结转移的影响因素并建立预测模型。应用预测模型分析其他34例NSCLC患者的淋巴结转移情况,以临床检测结果为金标准,评估预测模型的应用价值。
结果① 50例患者的淋巴结转移发生率为30.00%。转移组患者的术前癌胚抗原(CEA)、中央型隆突位置比率、淋巴结直径高于未转移组,差异有统计学意义(P < 0.05)。②转移组患者的淋巴结能谱曲线斜率(λHu)、标准化碘密度值(NIC)、淋巴结与原发病灶的λHu比值均低于未转移组,差异有统计学意义(P < 0.05)。③ NSCLC患者发生淋巴结转移的危险因素为淋巴结与原发病灶的λHu比值、术前CEA≥5 ng/mL、淋巴结直径≥3 cm。④ NSCLC患者淋巴结转移的预测模型诊断34例NSCLC患者的准确度、特异度、敏感度均在80.00%以上。
结论NSCLC患者淋巴结转移中可应用能谱CT参数以及临床病理因素中的相关危险因素建立预测模型进行准确预测,该模型可作为预测淋巴结转移的首选工具。
Abstract:ObjectiveTo explore the energy spectrum CT parameters, clinicopathological factors, influencing factors and the application efficiency of the prediction model of lymph node metastasis in patients with non-small cell lung cancer (NSCLC) at high altitude area.
MethodsA total of 84 NSCLC patients from January 2020 to July 2021 in Qinghai Provincial People′s Hospital were selected as research objects, of whom 50 patients were conducted with energy spectrum CT detection and their clinical materials were collected. According to the pathological examination results of lymph node metastasis, 50 patients were divided into metastasis group and non-metastasis group, the differences of clinicopathological factors and energy spectrum CT parameters between the two groups were analyzed by univariate analysis, the influencing factors of lymph node metastasis in NSCLC patients were analyzed by multivariate regression analysis, and a prediction model was established. The prediction model was used to analyze the lymph node metastasis of the other 34 NSCLC patients, and the clinical test results were used as the gold standard to evaluate the application value of the prediction model.
Results① The incidence of lymph node metastasis in 50 patients was 30.00%. The preoperative carcinoembryonic antigen (CEA), ratio of central carina position and lymph node diameter in the metastasis group were significantly higher than those in the non-metastasis group (P < 0.05). ② Slope of energy spectrum curve of lymph nodes (λHu), normalized iodine concentration (NIC) and λHu ratio of lymph nodes to primary lesions in the metastasis group were significantly lower than those in the non-metastasis group (P < 0.05). ③ The risk factors of lymph node metastasis in NSCLC patients were the λHu ratio of lymph nodes to primary lesions, preoperative CEA≥5 ng/mL and lymph node diameter≥3 cm. ④ The accuracy, specificity and sensitivity of the prediction model for lymph node metastasis in 34 patients with NSCLC were all above 80.00%.
ConclusionIn the NSCLC patients with lymph node metastasis, energy spectrum CT parameters and related risk factors in clinicopathological factors can be used to establish a prediction model for accurate prediction, and this model can be used as the preferred tool to predict lymph node metastasis.
-
-
表 1 NSCLC患者淋巴结转移临床特征的单因素分析[n(%)]
临床特征 分类 转移组(n=15) 未转移组(n=35) χ2 P 年龄 < 60岁 6(40.00) 16(45.71) 0.139 0.709 ≥60岁 9(60.00) 19(54.29) 性别 男 5(33.33) 16(45.71) 0.661 0.416 女 10(66.67) 19(54.29) 术前癌胚抗原 < 5 ng/mL 3(20.00) 24(68.57) 9.972 0.002 ≥5 ng/mL 12(80.00) 11(31.43) 淋巴结直径 < 3 cm 4(26.67) 22(62.86) 5.510 0.019 ≥3 cm 11(73.33) 13(37.14) 距隆突位置 中央型 10(66.67) 10(28.57) 6.349 0.012 周围型 5(33.33) 25(71.43) 吸烟史 是 7(46.67) 16(45.71) 0.004 0.951 否 8(53.33) 19(54.29) 表 2 转移组与未转移组能谱CT参数比较(x±s)
参数 转移组(n=15) 未转移组(n=35) 淋巴结λHu 1.82±0.57* 2.22±0.27 原发病灶λHu 1.71±0.47 1.67±0.43 淋巴结与原发病灶的λHu比值 1.02±0.22* 1.32±0.49 Neff-Z 0.79±0.02 0.78±0.02 IC 17.82±3.23 17.22±3.27 WC 1.00±0.01 1.00±0.02 NIC 0.22±0.02* 0.72±0.09 NWC 1.02±0.01 1.02±0.02 λHu: 能谱曲线斜率; Neff-Z: 标化有效原子序数; IC: 碘密度值; WC: 水密度值; NIC: 标准化碘密度值; NWC: 标准化水密度值。与未转移组比较, *P < 0.05。 表 3 变量赋值表
变量 编号 赋值 隆突位置 X1 1=中央型, 2=周围型 术前CEA X2 1=≥5 ng/mL, 2= < 5 ng/mL 淋巴结直径 X3 1=≥3 cm, 2= < 3 cm 淋巴结λHu X4 — 淋巴结与原发病灶的λHu比值 X5 — NIC X6 — 淋巴结转移 Y 1=是, 2=否 CEA: 癌胚抗原; λHu: 能谱曲线斜率; NIC: 标准化碘密度值。 表 4 多因素分析NSCLC患者淋巴结转移的影响因素
变量 非标准化系数 标准错误 标准系数 T P VIF 常数 2.689 0.560 — 4.799 < 0.001 — 术前CEA -0.403 0.115 -0.439 -3.497 0.001 1.055 淋巴结直径 0.337 0.119 -0.367 -2.829 0.007 1.127 距隆突位置 -0.088 0.127 -0.088 -0.688 0.495 1.085 淋巴结与原发病灶的λHu比值 0.463 0.174 -0.419 -2.332 0.004 1.032 淋巴结λHu -0.139 0.166 -0.107 -0.834 0.409 1.105 NIC -0.132 0.161 -0.102 -0.828 0.411 1.102 -
[1] CARBONE D P, RECK M, PAZ-ARES L, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer[J]. N Engl J Med, 2017, 376(25): 2415-2426. doi: 10.1056/NEJMoa1613493
[2] ETTINGER D S, WOOD D E, AISNER D L, et al. Non-small cell lung cancer, version 5. 2017, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2017, 15(4): 504-535. doi: 10.6004/jnccn.2017.0050
[3] 张娇, 赖远阳, 孙盈, 等. 非小细胞肺癌淋巴结转移与临床病理特征及预后的关系[J]. 现代肿瘤医学, 2019, 27(18): 3238-3241. doi: 10.3969/j.issn.1672-4992.2019.18.017 [4] SORIA J C, TAN D S W, CHIARI R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study[J]. Lancet, 2017, 389(10072): 917-929. doi: 10.1016/S0140-6736(17)30123-X
[5] POSTMUS P E, KERR K M, OUDKERK M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 28(suppl_4): iv1-iv21.
[6] FENNELL D A, SUMMERS Y, CADRANEL J, et al. Cisplatin in the modern era: the backbone of first-line chemotherapy for non-small cell lung cancer[J]. Cancer Treat Rev, 2016, 44: 42-50. doi: 10.1016/j.ctrv.2016.01.003
[7] KATAKAMI N, UCHINO J, YOKOYAMA T, et al. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and Cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04)[J]. Cancer, 2018, 124(3): 606-616. doi: 10.1002/cncr.31128
[8] LI A, WEI Z J, DING H, et al. Docetaxel versus docetaxel plus cisplatin for non-small-cell lung cancer: a meta-analysis of randomized clinical trials[J]. Oncotarget, 2017, 8(34): 57365-57378. doi: 10.18632/oncotarget.17071
[9] 陈盈, 姚琼瑛, 郑昊, 等. 能谱CT在肺癌淋巴结转移诊断中的临床应用研究[J]. 肿瘤学杂志, 2016, 22(8): 632-638. https://www.cnki.com.cn/Article/CJFDTOTAL-XHON201608005.htm [10] 李伟婷, 李永文, 张洪兵, 等. 基于TCGA数据库的中央型与周围型肺鳞癌基因表达差异性研究[J]. 中国肺癌杂志, 2019, 22(5): 280-288. https://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ201905005.htm [11] 申磊磊, 云天洋, 郭俊唐, 等. 左侧非小细胞肺癌4L组淋巴结转移的临床病理学特征及危险因素分析[J]. 南方医科大学学报, 2020, 40(12): 1793-1798. doi: 10.12122/j.issn.1673-4254.2020.12.14 [12] 李季, 沈艳, 姜研. CT仿真结肠镜联合肿瘤标志物检测在结直肠癌中的诊断价值[J]. 医学综述, 2021, 27(5): 1032-1036. doi: 10.3969/j.issn.1006-2084.2021.05.037 [13] 钱香, 王宏, 任真, 等. NLR与FIB和CEA及CA19-9在结直肠癌中的应用价值[J]. 中华预防医学杂志, 2021, 55(4): 499-505. doi: 10.3760/cma.j.cn112150-20200805-01094 [14] 龚麒麟, 边聪, 刘辉. 早期舌鳞状细胞癌颈隐匿性淋巴结转移的回顾性分析[J]. 中华耳鼻咽喉头颈外科杂志, 2016, 51(10): 773-775. doi: 10.3760/cma.j.issn.1673-0860.2016.10.012 -
期刊类型引用(4)
1. 曾海燕,杨小林. CT能谱参数对结直肠癌病理类型鉴别的价值. 中外医学研究. 2024(09): 64-67 . 百度学术 2. 王海波,段宏伟,左自军,丁琦峰,张鹏辉. 术前能谱CT多参数成像对晚期肺癌患者淋巴结转移的预测价值. 河南医学研究. 2024(06): 1071-1074 . 百度学术 3. 刘贲,张楠,邓治平. miR-126及Th1相关细胞因子在非小细胞肺癌患者血清中的表达水平及临床意义. 热带医学杂志. 2024(08): 1154-1158 . 百度学术 4. 周宇元. 增强CT联合能谱CT预测肺癌患者淋巴结转移的临床分析. 江西医药. 2024(07): 676-679 . 百度学术 其他类型引用(0)